Rallybio Corporation
RLYB
$0.66
$0.011.17%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -29.10% | -29.10% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.10% | -29.10% | -- | -- | -- |
| Cost of Revenue | -42.06% | -19.95% | -47.65% | -53.62% | -93.51% |
| Gross Profit | 48.94% | 14.16% | 49.59% | 53.86% | 95.76% |
| SG&A Expenses | -27.42% | -4.40% | -25.11% | -17.87% | -32.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.28% | -40.76% | -40.06% | -44.84% | -36.14% |
| Operating Income | 42.61% | 40.96% | 41.35% | 45.02% | 37.69% |
| Income Before Tax | 239.68% | 40.24% | 50.40% | 45.44% | 37.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 239.68% | 40.24% | 50.40% | 45.44% | 37.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 239.68% | 40.24% | 50.40% | 45.44% | 37.60% |
| EBIT | 42.61% | 40.96% | 41.35% | 45.02% | 37.69% |
| EBITDA | 42.75% | 41.00% | 41.39% | 45.07% | 37.73% |
| EPS Basic | 238.23% | 41.18% | 54.83% | 50.35% | 43.28% |
| Normalized Basic EPS | 45.43% | 41.22% | 45.33% | 50.34% | 42.04% |
| EPS Diluted | 238.23% | 41.18% | 54.83% | 50.35% | 43.28% |
| Normalized Diluted EPS | 45.43% | 41.22% | 45.33% | 50.34% | 42.04% |
| Average Basic Shares Outstanding | 1.04% | 1.62% | 9.81% | 9.89% | 10.02% |
| Average Diluted Shares Outstanding | 1.04% | 1.62% | 9.81% | 9.89% | 10.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |